Dimerization of a heat shock protein 90 inhibitor enhances inhibitory activity

被引：4

作者：

Wahyudi, Hendra ^{[1
]}

Wang, Yao ^{[1
]}

McAlpine, Shelli R. ^{[1
]}

机构：

[1] Univ New S Wales, Dept Chem, Sydney, NSW 2052, Australia

来源：

ORGANIC & BIOMOLECULAR CHEMISTRY | 2014年 / 12卷 / 05期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

SMALL-MOLECULE; SANSALVAMIDE; HSP90; CHAPERONE; DERIVATIVES; BINDING; HEAT-SHOCK-PROTEIN-90; CYTOTOXICITY; CONFORMATION; GELDANAMYCIN;

D O I：

10.1039/c3ob41722k

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Heat shock protein 90 (hsp90) accounts for 1-2% of the total proteins in normal cells and it functions as a dimer. Hsp90 behaves as a molecular chaperone that folds, assembles, and stabilizes client proteins. We have developed a novel hsp90 inhibitor, and herein we describe the synthesis and biological activity of the dimerized variant of this inhibitor. Tethering a monomer inhibitor together produced a dimerized compound that more effectively inhibits hsp90 over the monomer.

引用

页码：765 / 773

页数：9

共 50 条

[21] Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma (vol 8, e56134, 2013)
Wu, Xinqi
Marmarelis, Melina E.
Hodi, F. Stephen
PLOS ONE, 2024, 19 (08):
[22] Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor
Vesci, Loredana
Milazzo, Ferdinando Maria
Carollo, Valeria
Pace, Silvia
Giannini, Giuseppe
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (04) : 1421 - 1429
[23] Preclinical activity of the heat shock protein 90 inhibitor ganetespib in clear cell renal cell carcinoma.
Parasramka, Mansi
Proia, David A.
Joseph, Richard Wayne
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[24] Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800
Massey, Andrew J.
Schoepfer, Joseph
Brough, Paul A.
Brueggen, Josef
Chene, Patrick
Drysdale, Martin J.
Pfaar, Ulrike
Radimerski, Thomas
Ruetz, Stephan
Schweitzer, Alain
Wood, Mike
Garcia-Echeverria, Carlos
Jensen, Michael Rugaard
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (04) : 906 - 919
[25] Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures
Gulla, Aiste
Kazlauskas, Egidijus
Liang, Hong
Strupas, Kestutis
Petrauskas, Vytautas
Matulis, Daumantas
Eshleman, James R.
PANCREAS, 2021, 50 (04) : 625 - 632
[26] Irradiation facilitates the inhibitory effect of the heat shock protein 90 inhibitor NVP-BEP800 on the proliferation of malignant glioblastoma cells through attenuation of the upregulation of heat shock protein 70
Wu, Jianyue
Wang, Weimin
Shao, Qin
Xiao, Guomin
Cheng, Jun
Yuan, Yunpeng
Zhang, Mei
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (03) : 893 - 898
[27] AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)
Hobbs, Gabriella
Litvin, Rivka
Ahn, Jihae
Mckenney, Anna Sophia
Mauro, Michael J.
Tallman, Martin S.
Berman, Ellin
Heaney, Mark Lawrence
Levine, Ross L.
Rampal, Raajit K.
BLOOD, 2015, 126 (23)
[28] Antitumor activity of heat shock protein 90 (HSP90) inhibitor AT13387 in head and neck squamous cell carcinoma
Kristy Truong
Gouveia, Christopher
Coupar, Jamie
Smyth, Tomoko
Lyons, John
Chen, Zhong
Van Waes, Carter
CANCER RESEARCH, 2012, 72
[29] Preclinical antitumor activity of SST0116CL1, a novel heat shock protein 90 (HSP90) inhibitor
Vesci, Loredana
Milazzo, Ferdinando
Carollo, Valeria
Pace, Silvia
Giannini, Giuseppe
CANCER RESEARCH, 2014, 74 (19)
[30] Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression
Fang, Bing-Mu
Jiang, Jin-Hong
Zhang, Xue-Wu
Fan, Jian
Li, Shuang-Shuang
Tong, Xiang-Min
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (02) : 227 - 233

← 1 2 3 4 5 →